(4-氰苄基)三苯基氯化膦 | 20430-33-5

• 物质功能分类: 化学试剂 - 有机试剂 - 卤化磷
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-氰苄基)三苯基氯化膦
• 中文别名: (4-氰基苄基)三苯基氯化膦
• 英文名称: (4-cyanobenzyl)triphenylphosphonium chloride
• 英文别名: (4-cyanophenyl)methyl-triphenylphosphanium;chloride
• CAS: 20430-33-5
• 化学式: C₂₆H₂₁NP*Cl
• 分子量: 413.886
• InChiKey: GXMFPJIKPZDNCS-UHFFFAOYSA-M

物化性质

• 熔点：
  327-330 °C
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解。避免接触酸和氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.06
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22
• 海关编码：
  2931900090
• 危险品运输编号：
  3278
• 包装等级：
  III
• 危险类别：
  6.1
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密封装的容器中。储存时，请确保放在阴凉、干燥的地方。

SDS

Name:	4-Cyanobenzyltriphenylphosphonium chloride 98% Material Safety Data Sheet
Synonym:	None
CAS:	20430-33-5

Section 1 - Chemical Product MSDS Name:4-Cyanobenzyltriphenylphosphonium chloride 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
20430-33-5	4-Cyanobenzyltriphenylphosphonium chlo	98	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 20430-33-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Crystals
Color: white
Odor: none reported
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 327 - 330 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water: soluble
Specific Gravity/Density:
Molecular Formula: C26H21ClNP
Molecular Weight: 413.89

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Dust generation, excess heat.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, oxides of phosphorus, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 20430-33-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Cyanobenzyltriphenylphosphonium chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
WGK (Water Danger/Protection)
CAS# 20430-33-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 20430-33-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 20430-33-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4-氰苄基)三苯基氯化膦 在 18-冠醚-6 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 48.0h， 生成 [1,1′:4′,1″-terphenyl]-4-carbonitrile
  参考文献：
  名称：

  通过一锅法苯并二氮杂狄尔斯-阿尔德反式-1,2-二氯乙烯与二烯的反应合成对-三联苯和11,12-二氢茚并[ 2,1- a ]芴

  摘要：

  通过Diels-Alder反应的一锅法苯并环合反应，以1,2-二氯乙烯作为乙炔当量的亲二烯体，成功地合成了一系列取代的对-三联苯和11,12-二氢茚并[ 2,1- a ]芴。两个氯原子可能是良好的离去基团，易于在高温下随后发生Diels–Alder产品的消除反应。

  DOI：

  10.1016/j.tetlet.2013.02.002
• 作为产物：
  描述：

  三苯基膦 、 对氰基氯苄 以 苯 为溶剂， 反应 48.0h， 以89.3%的产率得到(4-氰苄基)三苯基氯化膦
  参考文献：
  名称：

  1,2-二苯乙烯-醚类作为伯醇的光不稳定保护基团，可根据波长选择提供可控的脱保护

  摘要：

  已经开发了新颖的二苯乙烯-醚类型的对羟基的光不稳定保护基（PPG）。它包含受保护形式的稳定的芳基醚基，可以在300 nm辐射下通过酸催化的光重排进行脱保护。选择性脱保护也已经通过在365nm处辐射4-烷氧基sti和2-（4-烷氧基苯乙烯基）呋喃的混合物来实现。

  DOI：

  10.1016/j.tet.2013.06.074

文献信息

• Quinoline derivatives as antagonists of leukotriene D.sub.4
  申请人：Rhone-Poulenc Rorer Pharmaceuticals Inc.

  公开号：US05051427A1

  公开（公告）日：1991-09-24

  This invention relates to certain quinoline-diaryl compounds and their use as leukotriene D.sub.4 antagonists for the treatment of hypersensitive disorders.

  这项发明涉及某些喹啉-二芳基化合物及其作为白三烯D.sub.4拮抗剂用于治疗过敏性疾病。
• Direct Wittig Olefination of Alcohols
  作者：Qiang-Qiang Li、Zaher Shah、Jian-Ping Qu、Yan-Biao Kang

  DOI：10.1021/acs.joc.7b02720

  日期：2018.1.5

  A base-promoted transition metal-free approach to substituted alkenes using alcohols under aerobic conditions using air as the inexpensive and clean oxidant is described. Aldehydes are relatively difficult to handle compared to corresponding alcohols due to their volatility and penchant to polymerize and autoxidize. Wittig ylides are easily oxidized to aldehydes and consequently form homo-olefination

  描述了在有氧条件下使用醇作为廉价且清洁的氧化剂，使用醇在碱性条件下使用无醇过渡醇取代烯烃的方法。与相应的醇相比，由于醛的挥发性和聚合和自氧化倾向，因此醛相对较难处理。维蒂希酸根易于氧化成醛，因此形成均烯烃化产物。首次通过同时原位生成乙叉和乙叉的策略，无需预先制备醛或乙叉醇就将醇直接转移到烯烃中。因此，实现了二醇的二/单可控烯烃化。这种合成实用的方法已用于克级合成的药物，如DMU-212和白藜芦醇。
• Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
  申请人：——

  公开号：US20040077605A1

  公开（公告）日：2004-04-22

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。
• Bicyclic heterocycles, the preparation thereof, and their use as
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06114532A1

  公开（公告）日：2000-09-05

  The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula ##STR1## wherein R.sub.a to R.sub.c, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. The compounds of the above formula I wherein R.sub.c denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein R.sub.c denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.

  本发明涉及公式##STR1##的5-成员杂环融合苯衍生物，其中R.sub.a至R.sub.c，A，X和Y的定义如权利要求1中所定义，其互变异构体，立体异构体，其混合物及其盐，特别是其与具有有价值性质的无机或有机酸或碱的生理上可接受的盐。上述公式I中R.sub.c表示氰基的化合物是制备公式I的其他化合物的有价值中间体，上述公式I中R.sub.c表示以下氨基甲酰基基团之一的化合物及其互变异构体和立体异构体具有有价值的药理学性质，特别是抗血栓活性。
• METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF
  申请人：Salvati E. Mark

  公开号：US20050119228A1

  公开（公告）日：2005-06-02

  Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

  融合的环化合物，使用这种化合物治疗与核激素受体相关的疾病，如癌症和免疫紊乱的方法，以及含有这种化合物的药物组合物。

表征谱图